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Pemphigus and bullous pemphigoid are mem-
bers of the chronic nonhereditary blistering skin 
diseases of man. Pemphigus, a skin disease con-
sidered universally fatal before the development of 
corticosteroid therapy, is characterized clinically 
by flaccid, weeping, bullous lesions that eventu-
ally become large denuded areas of skin. Involve-
ment of the mucous membranes is common and 
may represent the presenting symptomatology. 
The characteristic histopathology-in traepidermal 
bulla formation with loss of cohesion of the epi-
dermal cells (acantholysis)-is diagnostic of pem-
phigus [1]. 
Bullous pemphigoid, a disease with a much 
better prognosis, affects chiefly the elderly patient. 
It is characterized by large tense blisters involv-
ing primarily the intertriginous areas. Denuded and 
peripherally extending lesions, as seen in pem-
phigus, are rare in this disease. Histopathologically, 
subepidermal bullae are found in bullous pemphi-
goid [1]. 
SERUM ANTIBODIES 
With the use of immunofluorescent (IF) 
methods, which are particularly valuable in diag-
nosing and classifying bullous skin diseases, dis-
tinct immune responses and staining patterns 
have been recognized in- pemphigus and bullous 
pemphigoid. Autoantibodies specific for an inter-
cellular substance (ICS) of skin and mucosa are 
present in serum of patients who have pemphigus 
[2,3], whereas autoantibodies specific for the base-
ment membrane zone (BMZ) are present in bul-
lous pemphigoid sera [4,5]. "Pemphigus" anti-
bodies occur in all forms of true pemphigus includ-
ing pemphigus vulgaris, pemphigus foliaceus, 
pemphigus erythematosus (Senear-Usher syn-
drome), and Brazilian pemphigus foliaceus or 
"Fogo selvagem" [6]. "Pemphigoid" antibodies 
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BF/S: blister fluid-to-serum 
BMZ: basement membrane zone 
EDT A: ethylenediaminetetraaceticacid 
ICS: intercellular substance 
IF: immunofluorescent 
occur mainly in bullous pemphigoid, although they 
have recently been reported in a few cases of herpes 
gestationis, a subepidermal blistering disease of 
pregnancy [7]. Both pemphigus and bullous pem-
phigoid antibodies react precisely at their primary 
histopathologic sites, i.e., in pemphigus the ICS, 
and in bullous pemphigoid the BMZ. The presence 
of these antibodies in sera is helpful diagnostically 
and may be of considerable importance in the 
pathogenesis of these diseases. 
STUDIES OF SKIN LESIONS 
A modification of the direct IF method originally 
outlined by Coons and Kaplan [8] has been used 
extensively to detect bound immunoreactants in 
skin lesions of patients with pemphigus and bul-
lous pemphigoid. In pemphigus, IgG deposition 
localized in the ICS areas occurs in most skin and 
oral lesions [3,6]. This direct IF test is also useful 
diagnostically, especially in early cases and those 
in which the indirect IF test may be negative. 
Direct IF staining of bullous pemphigoid skin 
lesions also demonstrates IgG deposition, but to 
the BMZ rather than to the ICS [4,9]. In the 
absence of circulating pemphigoid antibodies, the 
presence of such in vivo-bound IgG assumes con-
siderable diagnostic import. 
Complement deposits in skin lesions are found in 
both diseases (Tab. 1). C3 deposition in pem-
phigus, initially noted by Cormane and Chorzelski 
[10], is present mainly in skin lesions before 
initiation of corticosteroid therapy [11,12]. De-
posits of early complement components (Clq and 
C4), in addition to C3, are also present in early 
acantholytic lesions of pemphigus, suggesting that 
the complement system (in particular the classical 
pathway) may contribute to the pathogenesis 
[12,13]. In addition, we have recently demon-
strated Factor B (C3 pro activator) deposition in 
some early lesions of pemphigus, whereas proper-
din deposition occurs rarely and only around a few 
individual acantholytic cells [13]. Figures lA and 
B depict Clq and C3 depositions in early skin 
lesions of pemphigus. 
In bullous pemphigoid, deposition of C3 in the 
BMZ has been demonstrated consistently in 
almost all skin lesions examined including caSf 'S 
with active disease but without circulating ant :-
bodies [9,14]. As in pemphigus, the direct IF 
pattern in bullous pemphigoid is identical to the 
indirect IF pattern. Provost and Tomasi [15] fiTfit 
reported that factors associated with the alternH-
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tive or properdin pathway are present in the skin 
lesions of bullous pemphigoid. Properdin and Fac-
tor B deposition was noted in addition to Clq, C4, 
and C3 deposition. They have recently extended 
these observations [16], and we have been able to 
confirm their findings [17]. Deposits of Factor B 
and properdin in bullous pemphigoid skin lesions 
are depicted in Figures 2A and B. 
Table I summarizes our findings of immuno-
reactants and fibrin in a series of pemphigus and 
bullous pemphigoid skin lesions examined with IF 
methods. 
IN VITRO COMPLEMENT STAINING 
Using in vitro complement staining methods, we 
have previously reported that most serologically 
positive bullous pemphigoid sera fix C3 to the 
BMZ [18]. Recently, we have extended those 
studies to show that bullous pemphigoid anti-
bodies will fix Clq and C4 (Fig. 3) in addition to C3 
[19]; these findings suggest that these antibodies 
activate the classical complement pathway. Most 
complement-fixing pemphigoid antibodies belong 
to the IgG3 subclass [20], which characteristically 
activates the classical pathway. Preliminary stud-
ies by us, however, suggest that BMZ antibodies 
may also fix properdin and Factor B in addition to 
Clq, C4, and C3 (unpublished observations). 
Selected control studies, demonstrating the 
specificity of the observed in vitro complement IF 
staining reactions with pemphigoid antibodies, 
appear in Table II. Heat inactivation (56°C for 30 
min), as well as addition of ethylenediaminetetraa-
cetic acid (EDTA) to the complement source, 
decreased the intensity of Clq and C4 staining and 
completely inhibited C3 staining. As reported by 
us previously [18], heat inactivation or addition of 
EDTA to the complement source does not affect 
IgG staining. Inhibition of the specific complement 
IF staining reactions was noted when the specific 
antisera to Clq, C4, and C3 were absorbed with 
purified Clq, C4, and C3, respectively [19]. 
TABLE 1. Summary of immunofluorescent studies of 
pemphigus and bullous pemphigoid skin lesionsG 
Pemphigush Pemphigoid" 
IgG 12/12 30/37 
IgM 3/12 7/37 
IgA 4/12 5/37 
Clq 7/12 32/37 
C4 4/6 10/11 
C3 12/12 37/37 
Factor B 7/12 13/37 
Properdin 3/12 35/37 
Fibrin 2/6 19/37 
G Ratios indicate number positive/number tested 
b ICS staining. Six cases were summarized previously 
[13 ] 
C BMZ staining. Fifteen cases were summarized previ-
ously [17] 
FIG. 1. Immunofluorescent staining of skin lesions of 
patients with pemphigus demonstrating ICS deposition. 
A: Clq deposition (x 250). B: C3 deposition ( x 250). 
To date we have not been able to demonstrate, 
by in vitro complement staining methods, that 
pemphigus antibodies fix complement [21]. This 
problem is somewhat disturbing since Clq, C4, 
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and C3 deposition occurs in most pemphigus skin 
lesions [11-13]. We have noted, however, that 
complement deposition in pemphigus lesions 
occurs only in areas of acantholysis (Fig. 2). 
Deposition of IgG, on the other hand, is more 
diffuse, occurring in uninvolved adjacent areas in 
addition to pathologic areas. It may be that only in 
acantholytic areas (affected areas) are the pem-
FIG. 2. Immunofluorescent staining of skin lesions of 
patients with bullous pemphigoid demonstrating BMZ 
deposition. A: Factor B deposition (x 250). B: Properdin 
deposition ( x 250). 
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FIG. 3. Immunofluorescent staining of normal human 
skin using in vitro C4 staining and bullous pemphigoid 
serum. Positive BMZ staining is evident (x 250). 
phigus antibodies so arranged that complement 
activation can occur. This discrepancy is being · 
investigated further. 
COMPLEMENT STUDIES 
Blister fluids of most serologically positive 
patients with bullous pemphigoid have reduced 
levels of total hemolytic complement when com-
pared to serum levels and other serum and blister 
fluid proteins [22,23]. Most serologically negative 
cases, however, had blister fluid complement levels 
approaching serum levels. Since pathologic fluid 
complement activity is related to the total protein 
content [24], serum and blister complement levels 
are expressed in terms of the total protein levels 
(CH50 units per 10 mg of total protein). The blister 
fluid-to-serum (BF/S) ratio is then an expression of 
the amount of complement in blister fluid com-
pared to that in serum. Figure 4 illustrates the 
relationship between BMZ antibody titer and the 
BF /S ratios in a series of patients with bullous 
pemphigoid. All of the serologically negative 
patients had BF /S ratios greater than 50%, 
whereas most of the serologically positive cases had 
BF/S ratios below 50%. 
Individual complement components appear to 
be decreased in bullous pemphigoid blister fluids 
with low complement levels, with the exception of 
the two terminal components, C8 and C9 [22]. 
Serum levels of the individual components of the 
complement sequence, however, are relatively nor-
mal. 
Levels of Factor B were not decreased in bullous 
pemphigoid blister fluids when measured by radial 
imm unodiffusion [22]. Indeed, several blister 
fluids exhibited higher levels of Factor B than their 
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TABLE II. Selected specificity control tests for in vitro CZ q, C4, and C3 staining reactionsa 
Antiserum Reactions Sample C treatmentb 
absorption Clq C4 C3 
Saline NoC 
Saline C 
NHS ,c 1:20 C 
Bullous pemphigoid serum: d 
1:20 NoC 
1:20 C +++ ++++ ++++ 
1:20 C 56°C for 30 min + + 
1:20 C plusEDTA ++ + 
1:20 C C1q ++++ ++++ 
1:20 C C4 +++ ++++ 
1:20 C C3 +++ ++++ 
a From Jordon et al [19 ] 
b C = complement 
C Normal human serum 
d Bullous pemphigoid serum, heat inactivated at 56°C for 30 min 
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FIG . 4. Correlation of blister fluid to serum ratios (the 
amount of total complement in blister fluid compared to 
that in serum) and the indirect IF antibody titer in 22 
patients with bullous pemphigoid. Most serologically 
positive cases had low BF /S ratios « 50%) while all 
serologically negative cases had higher BF /S ratios 
( > 50%). 
corresponding sera. When we tested such blister 
fluids by immunoelectrophoresis with antiserum to 
Factor B, however, conversion of Factor B was 
apparent but not in the corresponding serum. 
Preliminary studies [25] suggest that heat-stable 
chemotactic activity is present in most bullous 
TABLE III. Hemolytic complementa in the serum and 
blister fluid of patients with pemphigus vulgaris 
Cases 
1 2 3 4 5 
Serum (S) 14.9 13.4 13.0 11.6 17.2 
Blister fluid (BF) 3.4 5.0 < 1.0b 1.9 < 1.0b 
BF/S ratio (%)C 23 37 < 8 16 < 6 
Anticomplementary Yes No Yes Yes Yes 
activityd 
Inhibition (%)e 35 0 100 20 63 
a Expressed in CHso units/10 mg of total protein 
b Too low to measure 
C The ratio of complement in blister fluid to comple-
ment in serum 
d The ability of the patient's blister fluid to inhibit 
complement activity in an equal volume of normal 
human serum 
e The degree of inhibition produced by anticomple-
mentary action for each blister fluid sample 
pemphigoid blister fluids. Fluid from suction-
induced and cantharidin-induced blisters exerted 
some chemotactic activity but, in contrast with 
bullous pemphigoid blister fluids, this activity was 
almost entirely abolished by heat inactivation. In 
addition, the chemotactic activity of heat-inac-
tivated pemphigoid blister fluid was inhibited by 
N-CBZ-a-glutamyl-L-tyrosine-a compound that 
supposedly dissociates the macromolecular C567 
complex [26 ]-and by addition of antiserum to C5. 
Addition of antiserum to C3, on the other hand, 
did not inhibit this activity. 
Total hemolytic complement is decreased in 
pemphigus vulgaris blister fluids (Tab. III) when 
compared to serum complement levels and other 
proteins in serum and blister fluid [27]. With the 
exception of bullous pemphigoid blister fluids, 
most other bullous disease and experimentally 
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induced blisters had total complement levels in 
their blister fluids closely approaching those in 
their serum levels [22,27]. Hemolytic C1, C4, C2, 
C3, and C5, when measured in serum and blister 
fluid from three patients with pemphigus, were not 
detectable in one blister fluid and were extremely 
low in the other two. When measured immuno-
chemically, Factor B was absent from two pem-
phigus blister fluids tested. 
Four of five pemphigus blister fluids studied 
thus far have exhibited anticomplementary activ-
ity when tested with normal human serum (Tab. 
ITI). In addition, inhibition of hemolytic C 1, C2, 
C3, and C5 occurred when pemphigus blister fluid 
was added to normal human serum [27]. The 
anticomplementary factor of pemphigus blister 
fluid, therefore, also appears to activate the classi-
cal complement pathway. Similar inhibition stud-
ies using control sera and blister fluids failed to 
demonstrate such inactivation of hemolytic C1, 
C2, C3, and C5. 
Addition of pemphigus vulgaris blister fluid to 
normal human serum also resulted in conversion of 
both C3 and Factor B in the normal human serum 
when tested by immunoelectrophoresis [27]. Such 
Factor B activation of normal human serum by 
pemphigus blister fluid is probably best explained 
at the present time by C3b feedback activation of 
Factor B through Factor D [28,29]. Anticomple-
mentary activity of pemphigus blister fluid is not 
destroyed by heating to 56°C for 30 min, and it will 
activate complement both at 37 °C for 1 hr and at 
4°C for 8 hr. 
IMMUNE COMPLEX STUDIES 
Since the above studies suggested that immune 
complexes might be formed in pemphigus blister 
fluids, experiments were designed to characterize 
further the anticomplementary factor of blister 
fluid. Using sucrose density gradient ultracen-
trifugation methods and hemolytic complement 
assays, we found that the pemphigus blister fluid 
anticomplementary activity sedimented in high-
molecular-weight fractions with an S value of over 
19 [30]. In addition, significant anticomplemen-
tary activity was present in three of five bullous 
pemphigoid blister fluids tested by these same 
methods. This activity was also present in the 
bottom gradient fractions. None of the control 
blister fluids, including cantharidin-induced blis-
ters, suction-induced blisters, and blister fluids 
from a few patients with other bullous diseases, 
contained such activity. 
Six of 10 pemphigus sera tested thus far have 
also demonstrated similar anticomplementary ac-
tivity, but in these instances sedimentation 
occurred at about 12S and 19S. Two of five bullous 
pemphigoid sera also contained some anticom-
plementary activity, which corresponded in magni-
tude to the blister fluid activity. Activity in the 
blister fluids was always greater than in the 
c'orresponding sera. 
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As with pemphigus blister fluid alone, addition 
of positive-gradient fractions of both pemphigus 
and bullous pemphigoid blister fluids to fresh 
normal human serum resulted in consumption of 
both hemolytic C1 and C3. When these positive-
gradient fractions were added to guinea-pig serum 
genetically deficient in the fourth component of 
complement, no consumption of hemolytic C3 was 
noted. 
We have also recently developed a radioassay 
using 125I-Iabeled C1q as described by Nydegger et 
al [31]. After incubating test sera with 125I_C1q, the 
radioactivity present in a 1.5% polyethylene glycol 
precipitate is counted and compared to a standard 
curve prepared with heat-aggregated IgG. Of 110 
serum samples from 31 patients with active pem-
phigus tested thus far, 25 samples from 10 patients 
showed a significantly elevated binding of 125I_C1q 
[32). Five of eight sera from patients with systemic 
lupus erythematosus also exhibited elevated C1q-
binding as described by Nydegger et al [31). In 
contrast, sera from 30 normal donors exhibited -
consistently low levels of C1q precipitation. Stud-
ies of sera and blister fluids from patients with 
bullous pemphigoid are presently in progress. 
Thus, pemphigus and bullous pemphigoid repre-
sent autoimmune diseases of skin in which local 
activation of complement and, perhaps, immune 
complex formation occur. Whether local comple-
ment activation and immune complex formation 
contribute to the pathogenesis of these diseases, 
however, must still be determined. 
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DISCUSSION 
Gigli: Since a variety of proteolytic enzymes can 
activate the complement system, I wonder whether some 
of the enzymes liberated from cells into the blister fluid 
could be responsible for the complement utilization seen. 
Jordon: Complement activation in pemphigus and 
pemphigoid blister fluids by enzymes cannot be ruled 
out; enzymes probably play some role. In an attempt to 
approach this problem we chose to study cantharidin-
induced blisters, which are inflammatory blisters, as 
controls. Complement levels in these blister fluids are 
relatively high when compared to those in pemiphigus 
and bullous pemphigoid blister fluids. In addition we 
have recently identified heat-stable chemotactic activity 
in bullous pemphigoid blister fluids which we believe is 
complement derived. Similar activity was not present in 
cantharidin-induced blister fluids. 
Provost: Please comment on the finding of IgG and 
complement deposition in "normal skin" of some bullous 
pemphigoid patients. 
Jordon: In our experience IgG deposition is occasion-
ally found in normal skin in bullous pemphigoid, but C3 
deposition in such areas occurs infrequently. In contrast, 
heavy deposition of C3 and other complement compo-
nents occurs in lesional areas. 
Agnello: The approach of comparing results from the 
radioimmunoassays employing C1q or rheumatoid factor 
is useful not only in confirming the presence of immune 
complexes but also in detecting nonimmune C1 react-
ants. Have you looked at your data in this way, that is, 
for sera inhibiting C1q binding but not rheumatoid factor 
binding? 
Jordon: We have not had the opportunity to compare 
our radio-C1q assay results with Dr. McDuffie's radio-
rheumatoid-factor assay results, as the latter results are 
preliminary. Such studies, however, are currently in 
progress. 
Austen: Can you clarify the complement pathways in 
the two forms of bullous diseases, that is, which pathway 
in which disease? 
Jordon: Our immunofluorescent studies, hemolyti~ 
complement studies, and studies of the anticomplemen L 
tary factors suggest classical pathway activation of com-
plement in both pemphigus and bullous pemphigoid. In 
this respect, then, these diseases are similar. Properdin 
deposition does occur in pemphigoid skin lesions but 
rarely in pemphigus. We now think, however, that such 
BMZ deposition of properdin may be due to the presence 
of C3b at the same site following classical pathway 
activation. 
Lazarus: There are probably proteolytic mechanisms 
in human epidermis which are capable of activating 
complement. Hatcher and I have purified a human 
lysosomal epidermal proteinase which is chemotactic for 
polymorphonuclear leukocytes. Preliminary studies in 
association with Drs. Irma Gigli and Ralph Snyderman 
suggest that proteinase-induced chemotaxis is dependent 
upon complement activation . Consequently, it is possible 
that epidermal injury could release this neutral serine 
proteinase and activate complement independent of ,an 
immunologic mechanism. 
In support of Dr. Jordon's hypothesis that complement 
activation is immunologic are his control studies with 
cantharidin. Cantharidin initially labilizes lysosomes 
and then causes cell death and cytolysis. Consequently, 
one would expect that if complement consumption were 
secondary to the release of epidermal factors such as 
proteinase, then cantharidin blister fluid should have 
decreased complement. The lack of complement con-
sumption in cantharidin blister fluid implies that at least 
with regard to complement fixation in blister fluid, 
immune complexes may playa role in pemphigus. 
Katz: Have you produced these cantharidin or suction 
blisters in patients whose spontaneous blisters you stud-
ied? 
Jordon: We did not produce suction or cantharidin 
blisters on patients with pemphigus and bullous pem-
phigoid. These experimental blisters were produced on 
healthy volunteers. 
Kantor: In view of the several seronegative patients, 
what is the impelling evidence that the antibodies and 
complement fixation seen in bullous diseases are in fact 
related to the pathogenesis of the disease? 
Jordon: Seronegative cases occur in both pemphigus 
and bullous pemphigoid . Although serum samples may 
not contain the specific antibodies, by direct immuno-
fluorescence one finds immunoglobulin and complement 
deposition in the ICS areas in pemphigus lesions and the 
BMZ in bullous pemphigoid lesions. Negative direct 
immunofluorescent findings in these diseases must be 
rare if they occur at all. 
Bystryn: There is another troublesome clinical obser-
vation that relates to the pathologic role of complement 
activation. In both bullous pemphigoid and lupus ery-
thematosus, deposits of immunoglobulin and comple-
ment are present in essentially the same location at the 
dermal-epidermal junction, yet the skin lesions which 
characterize these diseases are quite different. Bullae are 
typical of bullous pemphigoid but are very rare in lupus 
erythematosus. 
Jordon: The immune mechanisms in the skin in 
bullous pemphigoid and systemic lupus erythematosus 
are quite different. But why one mechanism leads to 
blister formation while the other does not remains a 
mystery. 
